Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Stock Holdings Reduced by Sio Capital Management LLC

Sio Capital Management LLC trimmed its position in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 17.9% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 127,511 shares of the medical equipment provider’s stock after selling 27,793 shares during the quarter. Zimmer Biomet makes up 5.5% of Sio Capital Management LLC’s portfolio, making the stock its 4th biggest holding. Sio Capital Management LLC owned 0.06% of Zimmer Biomet worth $13,765,000 at the end of the most recent quarter.

Other hedge funds also recently modified their holdings of the company. American Century Companies Inc. boosted its position in Zimmer Biomet by 12.6% during the second quarter. American Century Companies Inc. now owns 6,463,845 shares of the medical equipment provider’s stock worth $701,521,000 after acquiring an additional 722,041 shares during the last quarter. Van ECK Associates Corp boosted its holdings in shares of Zimmer Biomet by 12.4% during the third quarter. Van ECK Associates Corp now owns 3,736,761 shares of the medical equipment provider’s stock worth $391,239,000 after purchasing an additional 411,163 shares during the last quarter. Victory Capital Management Inc. grew its position in shares of Zimmer Biomet by 6.7% in the second quarter. Victory Capital Management Inc. now owns 3,364,624 shares of the medical equipment provider’s stock valued at $365,163,000 after purchasing an additional 211,637 shares during the period. Allspring Global Investments Holdings LLC increased its stake in Zimmer Biomet by 0.4% in the third quarter. Allspring Global Investments Holdings LLC now owns 2,569,311 shares of the medical equipment provider’s stock valued at $277,357,000 after purchasing an additional 9,990 shares during the last quarter. Finally, Dimensional Fund Advisors LP lifted its position in Zimmer Biomet by 9.3% during the second quarter. Dimensional Fund Advisors LP now owns 1,810,770 shares of the medical equipment provider’s stock worth $196,523,000 after buying an additional 154,447 shares during the period. 88.89% of the stock is owned by institutional investors and hedge funds.

Zimmer Biomet Trading Up 1.2 %

NYSE:ZBH opened at $112.02 on Friday. Zimmer Biomet Holdings, Inc. has a 12-month low of $101.47 and a 12-month high of $133.90. The company has a debt-to-equity ratio of 0.38, a current ratio of 1.36 and a quick ratio of 0.70. The business has a 50 day simple moving average of $107.18 and a 200 day simple moving average of $109.50. The firm has a market capitalization of $22.30 billion, a P/E ratio of 21.30, a P/E/G ratio of 2.06 and a beta of 1.02.

Zimmer Biomet (NYSE:ZBH) last posted its earnings results on Wednesday, October 30th. The medical equipment provider reported $1.74 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $1.74. The firm had revenue of $1.82 billion during the quarter, compared to analyst estimates of $1.80 billion. Zimmer Biomet had a net margin of 14.27% and a return on equity of 12.95%. Zimmer Biomet’s revenue was up 4.1% on a year-over-year basis. During the same period in the previous year, the business posted $1.65 EPS. Equities research analysts predict that Zimmer Biomet Holdings, Inc. will post 7.99 EPS for the current year.

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on ZBH shares. BTIG Research cut their price objective on shares of Zimmer Biomet from $134.00 to $126.00 and set a “buy” rating on the stock in a report on Thursday, October 3rd. Wolfe Research initiated coverage on shares of Zimmer Biomet in a research note on Tuesday, September 10th. They issued a “peer perform” rating on the stock. Royal Bank of Canada upped their price target on shares of Zimmer Biomet from $120.00 to $125.00 and gave the stock an “outperform” rating in a research report on Monday, November 4th. Robert W. Baird reduced their price objective on Zimmer Biomet from $155.00 to $145.00 and set an “outperform” rating on the stock in a research note on Thursday, August 8th. Finally, JPMorgan Chase & Co. lowered their target price on Zimmer Biomet from $125.00 to $120.00 and set a “neutral” rating for the company in a research note on Monday, September 16th. Two research analysts have rated the stock with a sell rating, twelve have assigned a hold rating and seven have given a buy rating to the company. According to MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $123.22.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.